Across TCGA pan-cancer cohorts, CARHSP1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CARHSP1 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CARHSP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CARHSP1 expression acts as an unfavorable survival marker.
LUSC and CHOL are the cancer types where CARHSP1 Mutation most reproducibly stratifies survival.